亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

        2021-01-07 23:21:09EdwardWalshetal
        四川生理科學(xué)雜志 2021年1期

        Edward E Walsh, et al.

        Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease,coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.Multiple vaccine candidates are under development, but no vaccine is currently available.Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States.

        Methods: In an ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted in the United States,we randomly assigned healthy adults 18 to 55 years of age and those 65 to 85 years of age to receive either placebo or one of two lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 receptor-binding domain; or BNT162b2, which encodes a membrane-anchored SARS-CoV-2 full-length spike, stabilized in the prefusion conformation.The primary outcome was safety (e.g., local and systemic reactions and adverse events); immunogenicity was a secondary outcome.Trial groups were defined according to vaccine candidate, age of the participants, and vaccine dose level (10 μg, 20 μg, 30 μg, and 100 μg).In all groups but one, participants received two doses, with a 21-day interval between doses; in one group (100 μg of BNT162b1), participants received one dose.

        Results: A total of 195 participants underwent randomization.In each of 13 groups of 15 participants, 12 participants received vaccine and 3 received placebo.BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults.In both younger and older adults, the two vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing geometric mean titers, which were similar to or higher than the geometric mean titer of a panel of SARS-CoV-2 convalescent serum samples.

        Conclusions: The safety and immunogenicity data from this U.S.phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation.(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

        亚洲日韩av无码| 老熟女的中文字幕欲望| 国产超碰人人做人人爽av大片| 亚洲av无码第一区二区三区| 国产莉萝无码av在线播放| 亚洲午夜精品久久久久久人妖| 国产精品久久久久免费看| 精品一区二区三区a桃蜜| 蜜桃91精品一区二区三区| 欧美性高清另类videosex| 一本色道久久99一综合| 欧美日韩一区二区三区色综合| 精品国产污黄网站在线观看| 国产美女高潮流白浆免费视频| 亚洲色大成网站www久久九| 欧美老妇与禽交| 久久青草国产精品一区| 亚洲av色精品国产一区二区三区| 亚洲一区二区三区99| 中文字幕人妻中文| 欧美成人专区| 最近中文字幕一区二区三区| 亚洲av无码国产精品色午夜软件| 天天爽夜夜爽夜夜爽| 国产性一交一乱一伦一色一情| 亚洲精品中文字幕不卡| 蜜臀性色av免费| 免费观看国产精品| 无码AV午夜福利一区| 亚洲av高清不卡免费在线| 成人无码一区二区三区| 亚洲av无码片在线观看| 四虎无码精品a∨在线观看 | 男女18视频免费网站| 亚洲av无码av制服另类专区| 呦泬泬精品导航| 日本一区二区三区精品免费| 乱色精品无码一区二区国产盗 | 在线亚洲日本一区二区| 寂寞少妇做spa按摩无码| 亚洲av无码专区在线电影|